Johnson & Johnson to invest $2B in US manufacturing expansion in North Carolina

Johnson & Johnson is investing $2 billion over the next decade to expand its US manufacturing capacity through a new 160,000-square-foot facility at FUJIFILM's biopharmaceutical site in Holly Springs, North Carolina. The move is expected to create around 120 jobs. The investment aims to boost the company's production capabilities and support its growth in the biopharmaceutical sector.

Johnson & Johnson (J&J) has announced a significant investment in its U.S. manufacturing capacity by committing $2 billion over the next decade to a new 160,000-square-foot facility at Fujifilm Diosynth’s biomanufacturing campus in Holly Springs, North Carolina. The move is expected to create approximately 120 new jobs in the state. This investment aims to enhance J&J's production capabilities and support its growth in the biopharmaceutical sector.

The new facility, which is scheduled to come online this fall, will be part of a broader strategy by J&J to manufacture a majority of its advanced medicines in the U.S. In March, the company laid out a four-year, $55 billion investment plan to support manufacturing, R&D, and technology in the U.S. This latest announcement builds on that plan, with J&J also planning to share additional advanced manufacturing facility plans and expansions of current U.S. sites in the coming months.

Fujifilm Diosynth's Holly Springs campus, which is set to employ roughly 1,400 by 2031, is already a significant player in the biologics production landscape. The company has also recently signed a 10-year, $3 billion deal with Regeneron to produce biologics at the site. J&J's investment is part of a broader trend in the pharmaceutical industry, driven by the Trump administration's push to impose import tariffs on foreign-made medicines.

J&J CEO Joaquin Duato emphasized the company's commitment to expanding its U.S. manufacturing presence. He stated, "Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country, and we continue to strengthen our presence here. With the recent signing of the One Big Beautiful Bill Act, we continue to expand our investment in the U.S. to lead the next era of healthcare innovation."

The One Big Beautiful Bill Act, signed into law by President Trump in July, extends existing tax breaks and incentives for reshoring and onshoring manufacturing to the U.S. This legislation has been welcomed by the pharmaceutical industry as it encourages companies to invest in domestic manufacturing.

References:
[1] https://www.fiercepharma.com/manufacturing/us-manufacturing-push-jj-earmarks-2b-fujifilm-10-year-deal
[2] https://seekingalpha.com/news/4487767-johnson-johnson-unveils-2b-us-manufacturing-expansion-in-north-carolina
[3] https://www.marketscreener.com/news/johnson-johnson-opens-new-production-site-in-us-ce7c51d3dc8bf325
[4] https://pharmaphorum.com/news/jj-earmarks-2bn-facility-north-carolina
[5] https://www.marketscreener.com/news/johnson-johnson-continues-u-s-investment-with-2-billion-commitment-to-enable-manufacturing-at-no-ce7c51d3d088f424